Ultime notizie per Nuvectis Pharma (NASDAQ:NVCT) Azioni

Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Nuvectis Pharma Inc

WIIM

CVCO

Cavo Industries shares are trading higher after the company reported better-than-expected Q2 financial results and announced a $100 million stock repurchase program.

<p><a href="https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data">https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data</a></p>
<p><a href="https://www.bloomberg.com/quote/FB:US">Meta Platforms Inc.</a> failed in a bid to challenge a class action suit in the UK that alleged Facebook abused its dominant position and exploited its users personal data.</p>
<p>The <a href="https://www.bloomberg.com/quote/6152Z:LN">UK</a>'s Court of Appeal refused to permit Meta and Facebook's UK unit to challenge a competition appeals court which had greenlit a revised version of the lawsuit. The court rejected Meta's appeal at a hearing on October 7, but only published the detailed ruling on Friday.</p>


News

Legal

'Meta Loses Bid To Appeal UK Class Action Over User Data' - Bloomberg News

<p>Guggenheim  analyst Shahriar Pourreza   maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Buy and raises the price target from $145 to $165.</p>


Price Target

Analyst Ratings

Guggenheim Maintains Buy on Entergy, Raises Price Target to $165

PATK

Patrick Industries shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, Raymond James lowered its price target on the stock from $160 to $138.

<p>Guggenheim  analyst Robert Drbul   maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $80 to $100.</p>


Guggenheim Maintains Buy on Kontoor Brands, Raises Price Target to $100

VRRM

Verra Mobility shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 revenue guidance below estimates. Also, Barid and Deutsche Bank lowered their respective price targets on the stock.

ONTO

Onto Innovation shares are trading lower after Needham cut its price target on the stock from $245 to $230.

<p><strong>Microsoft Corp</strong>.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) decision to shut down Arkane Austin, the studio behind acclaimed titles like Redfall and Prey, has faced blunt criticism from industry veteran and Arkane founder<strong> Raphaël Colantonio.</strong> </p>
<p>Colantonio, now leading WolfEye Studios, described the decision <a href="https://www.pcgamer.com/games/microsoft-closing-arkane-austin-was-a-dumb-move-says-founder-and-former-president/">to</a> PC Gamer as "stupid" and "not a good decision."</p>
<h3 class="wp-block-heading"><strong>A &#8216;Special Group&#8217; Cut In A Corporate Reshuffle</strong></h3>
<p>Reflecting on the closure, Colantonio said: "I think if you look a little bit, it&#8217;s obvious that Arkane Austin was a very special group of people that have made some cool things and that could pull it off again." </p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/gaming/24/06/39417676/microsoft-issues-redfall-hero-pass-dlc-refunds-after-arkane-austin-closure">Microsoft Issues Redfall Hero Pass DLC Refunds After Arkane Austin Closure</a></strong></p>
<p>He added: "I think it was a decision that just came down to, &#8216;We need to cut something.&#8217; Was it to please the investors, the stock market? They&#8217;re playing a different game."</p>
<p>The closure of Arkane Austin, alongside studios like Tango Gameworks and Alpha Dog Games, formed part of a broader reorganization within Microsoft, which had announced plans to reduce its gaming division workforce by 1,900 employees. </p>
<p>In a memo, Xbox Game Studios head <strong>Matt Booty</strong> cited "reprioritization of titles and resources" as the driving force behind the cuts. </p>
<p>While Microsoft&#8217;s CEO <strong>Satya Nadella</strong> received a notable pay raise to $30 million last year, the company continues to grapple with evolving industry demands and cost pressures.</p>
<h3 class="wp-block-heading">Irreplaceable Talent And The Challenge Of Rebuilding</h3>
<p>Colantonio doubted whether the unique chemistry at Arkane Austin could ever be replicated. He pointed to key team members like <strong>Harvey Smith </strong>and<strong> Ricardo Bare</strong>, whose collaboration played a huge role in the studio&#8217;s achievements. </p>
<p>"When you have that magic of Harvey and Ricardo etc. that all come together, it&#8217;s a specific moment in time and space that just worked out this way, that took forever to reach,&#8221; he said. &#8220;Those people together can really make magic."</p>
<p>"It's not like, &#8216;Doesn&#8217;t matter, we&#8217;ll just rehire.&#8217; No, try it. That's what big groups do all the time. They try to just hire massively and overpay people to create those magic groups. It doesn't work like this. So to me, that was stupid. But what do I know?"</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/06/39534876/bethesda-game-studios-montreal-announces-unionization-plans">Bethesda Game Studios Montreal Announces Unionization Plans</a></li>
</ul>
<p><em>Image credits: Shutterstock.</em></p>


Gaming

General

MSFT

Microsoft's Decision To Shut Down Arkane Austin Called 'Stupid' By Studio Founder

MDGL

Madrigal Pharmaceuticals shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $411 to $441.

MDU Resources shares are trading lower. Everus Construction Group completed its spinoff from the company.

<p>Benchmark  analyst Josh Sullivan   maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $150 to $300.</p>


FTAI

Benchmark Maintains Buy on FTAI Aviation, Raises Price Target to $300

ARES

Ares Management shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Church & Dwight shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance.

<ul>
<li><strong>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</strong></li>
<li><strong>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</strong></li>
<li><strong>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</strong></li>
</ul>
<p>TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.</p>


Biotech

TEVA

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

MBLY

Mobileye Global shares are trading higher after Baird and TD Cowen raised their respective price targets on the stock.

<p>Investment firm <strong>21Shares</strong> submitted a request to the U.S. Securities and Exchange Commission (SEC) for approval to launch a spot <strong>XRP</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">exchange-traded fund (ETF)</a>.</p>
<p><strong>What Happened:</strong> 21Shares <a href="https://www.sec.gov/Archives/edgar/data/2028835/000121390024093305/ea0219336-01.htm">filed</a> an S-1 registration statement with the SEC on Friday proposing a fund, named the 21Shares Core XRP Trust to be listed on the Cboe BZX Exchange. Coinbase Custody Trust Company is expected to serve as the fund&#8217;s custodian.</p>
<p>This move is part of 21Shares&#8217; ongoing efforts to expand U.S. investor access to the cryptocurrency asset class. The firm joins a growing list of companies competing for different crypto ETFs, following the SEC&#8217;s initial approval of crypto ETFs earlier this year.</p>
<p>The Block <a href="https://www.theblock.co/post/324186/21shares-looks-to-secure-sec-approval-for-xrp-etf-amid-growing-interest-in-other-crypto-funds?utm_source=rss&amp;utm_medium=rss">reported</a> that Canary Capital and Bitwise are among the other firms applying for a spot XRP ETF despite possible challenges.</p>
<p>The SEC has previously been <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41157465/gary-genslers-sec-appeals-2023-ruling-against-ripple-labs-xrp-tanks-10-just-prolongs-compl">involved in a legal dispute with Ripple</a>, accusing the company of raising $1.3 billion through the sale of XRP, which it considers an unregistered security. The case between Ripple and the SEC is still ongoing.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41653546/blackrocks-bitcoin-etf-crosses-1-million-btc-in-assets-under-management">BlackRock&#8217;s Bitcoin ETF Crosses 1 Million BTC In Assets Under Management</a></strong></p>
<p><strong>Why It Matters:</strong> The recent move by 21Shares to seek approval for an XRP ETF indicates a growing trend among investment firms to broaden investor access to the cryptocurrency market through ETFs.</p>
<p>This development comes in the wake of increased interest in cryptocurrency ETFs. In July 2024, Cboe Global Markets Inc. had submitted a request to the SEC to list<strong> Solana </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) spot exchange-traded funds applied by VanEck and 21Shares. If approved, these would be the <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39679535/solana-jumps-5-5-as-cboe-files-application-with-sec-to-list-vaneck-21shares-spot-etfs">first ETF products linked to Solana.</a></p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41584575/bitcoin-etfs-vs-ethereum-etfs-why-does-eth-keep-underperforming">Bitcoin ETFs Vs Ethereum ETFs: Why Does ETH Keep Underperforming?</a></strong></li>
</ul>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

$XRP

XRP ETF Coming Soon? 21Shares Files For One Despite Ripple's Legal Battles

<p>Each week,&nbsp;<strong>Benzinga's Stock Whisper Index</strong>&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.</p>
<p>Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.</p>
<p><strong>Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE – Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></strong></p>
<p><strong>Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Nov. 1:</strong></p>
<p><strong>Agilent Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) saw increased interest from investors during the week, which comes ahead of several potential catalysts. The life sciences and diagnostics company is set to report fourth-quarter financial results on Nov. 25 and host an analyst day on Dec. 17. Recent <a href="https://www.benzinga.com/quote/A/analyst-ratings">analyst activity</a> on the stock saw Barclays maintain an Underweight rating while raising the price target from $135 to $145. Evercore ISI maintains an In-Line rating while raising the price target from $135 to $145. The stock was up over 3% in the last five trading days as shown on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below. It remains down around 2% year-to-date in 2024.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="462" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png" alt="" class="wp-image-626124" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-300x138.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143840/Screenshot-227-768x354.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure></p>
<p><strong>Trade Desk</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) saw increased interest from investors ahead of third-quarter financial results, which are set for Nov. 7. Analysts expect the company to report earnings per share of 39 cents and revenue of $619.8 million, compared to earnings of 33 cents per share and revenue of $493.3 million in last year's third quarter. Trade Desk has beaten earnings per share estimates in seven of the last eight quarters and beaten revenue estimates from analysts in more than 10 straight quarters.</p>
<p>Wedbush analyst Daniel Ives <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41144914/meta-trade-desk-amazon-digital-ad-titans-set-for-strong-2025-growth-tech-analyst-sa">recently highlighted </a>the growth potential for Trade Desk in the third quarter.</p>
<p>&#8220;Our survey showed accelerating growth for TTD in 3Q versus 2Q,&#8221; Ives said.</p>
<p>Trade Desk's <a href="https://www.benzinga.com/news/earnings/24/08/40267737/the-trade-desk-stock-climbs-after-better-than-expected-q2-results">second-quarter results</a> saw a customer retention rate of over 95%, continuing a 10-year streak. With potential strong growth and AI initiatives being integrated, the stock could generate some buzz with its third-quarter results.</p>
<p>The stock was down slightly over the last five days, but is up around 70% year-to-date.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png" alt="" class="wp-image-626125" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143856/Screenshot-228-768x384.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure></p>
<p><strong>Schwab US Dividend Equity ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) made the list for the first time. The Stock Whisper Index typically highlights only stocks and leaves the ETFs out. But each week, ETFs like the SPY, QQQ and sometimes other well-known ETFs see rising interest based on volatility. Schwab tracks the Dow Jones U.S. Dividend 100 Index. It offers investors exposure to some of the largest U.S. companies that pay dividends and have a strong track record of paying out dividends. Top holdings in the ETF include<strong> Bristol Myers Squibb, Blackrock, Cisco Systems, Home Depot </strong>and <strong>Chevron.</strong></p>
<p>With rising global tensions, macroeconomic uncertainties and the 2024 presidential election leaving some investors on edge, the ETF could be seeing increased interest thanks to its dividend income and positions in blue chip companies.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png" alt="" class="wp-image-626126" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143913/Screenshot-229-768x394.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure></p>
<p><strong>Reinsurance Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>): The life and health reinsurance company saw increased interest over the week likely due to quarterly financial <a href="https://investor.rgare.com/news-releases/news-release-details/reinsurance-group-america-reports-record-third-quarter-results">results</a>. The company reported third-quarter earnings per share of $6.13 and revenue of $5.65 billion, beating Street consensus estimates according to Benzinga Pro. Reinsurance Group's third quarter had record financial results. The strong quarter could put the stock on investors radar for future growth opportunities.</p>
<p>Shares of the reinsurance company were up around 2% for the last five days and are up over 30% year-to-date in 2024.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png" alt="" class="wp-image-626127" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143928/Screenshot-230-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure></p>
<p><strong>Sera Prognostics </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is scheduled to report third-quarter financial results on Nov. 6. The company is behind the PreTRM test for pregnancy preterm testing. An investor presentation highlighted the company's future product pipeline to include a predictive analytics product and a time-to-birth test. Shares of the pregnancy diagnostics company were up 16% over the last five trading days.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png" alt="" class="wp-image-626128" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01143943/Screenshot-231-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure></p>
<p><em>Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and</em>&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener"><em>top market-moving stories here.</em></a></p>
<p><strong>Read the latest Stock Whisper Index reports here:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 4</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/10/41296909/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 11</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 25</a></li>
</ul>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet</a></strong></li>
</ul>


Exclusives

Trading Ideas

SCHD

SERA

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

MSTR

MicroStrategy shares are trading lower. The company may be moving on continued weakness after reporting worse-than-expected Q3 financial results on Wednesday.

<p>Zions Bancorporation, N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) announced today that its board of directors ("board") declared a regular quarterly dividend of $0.43 per common share, payable November 21, 2024, to shareholders of record at the close of business on November 14, 2024.</p>


Dividends

ZION

Zions Bancorporation Increases Quarterly Dividend From $0.41 To $0.43 Per Share

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvectis Pharma (NVCT – Research Report) and Invivyd...

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)

Nuvectis Pharma Q1 EPS of -$0.25

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Nuvectis Pharma reported earnings per share of -25 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/nvct-stock-earnings-nuvectis-pharma-for-q1-of-2024/">NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $21.00...

Strong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug Trials

Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

Nuvectis Pharma reports Q2 results

Nuvectis Pharma (NVCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis fro...

Nuvectis Pharma: Strong Buy Rating on Solid Financials and Promising Oncology Pipeline

Nuvectis gains on FDA's orphan drug designation for cancer therapy

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target...

Nuvectis Pharma (NVCT) Gets a Buy from Roth MKM

AFMD

ANIX

FGEN

GNTA

IVVD

LPCN

NVCT

RLMD

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Press Releases

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Comments

Nuvectis Pharma

Notizie

Ultime notizie per Nuvectis Pharma (NASDAQ:NVCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO